Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system

靶向 p38/JNK MAPK 改善顺铂引起的神经系统不良后遗症

基本信息

  • 批准号:
    10668361
  • 负责人:
  • 金额:
    $ 61.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-01 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Chemotherapy-related cognitive impairment (CRCI, chemobrain), chemotherapy-induced peripheral neuropathy (CIPN) and gait changes are debilitating side-effects of cancer treatment with platinum agents (e.g., cisplatin), taxanes, and vinca alkaloids. Cisplatin is widely used as a chemotherapeutic agent to treat ovarian malignancies. Over 70% of women report experiencing CRCI, CIPN and/or falls during treatment or after completion, impairing their quality of life. These neurotoxic impairments can also compromise treatment with cisplatin, influencing disease progression. Currently, there are no FDA-approved clinical interventions for the treatment of CRCI and CIPN. Mechanistically, cisplatin-induced neuronal toxicity derives from nuclear and mitochondrial DNA damage, and oxidative stress, which induce the activation of the mitogen-activated protein kinases (MAPK), p38MAPK and c-Jun N-terminal kinase (JNK), leading to neuronal apoptosis. Our preliminary data show that in vitro pharmacological inhibition with small molecule inhibitors, i.e., neflamapimod for p38MAPK and SP600125 for JNK, prevents cisplatin-induced reduction in dendritic spine branching and density. Based on these data, we hypothesize that inhibition of the p38MAPK/JNK pathways will prevent cisplatin-induced neuronal apoptosis and damage, leading to attenuation of cognitive impairments, gait changes, and neuropathic pain associated with CRCI and CIPN. In this project, we propose to determine if: (1) cisplatin-induced p38 MAPK/JNK signaling underlies structural and functional neuronal damage, using in vitro pharmacological inhibition and siRNA silencing; (2) neflamapimod and SP600125 prevent cisplatin-induced neuropathy and gait alterations in the ID8 syngeneic epithelial ovarian cancer in C57BL/6 mice and the transgenic breast cancer model C3TAg in FVBN mice; and (3) cisplatin-induced neurotoxicity is attenuated by p38MAPK/JNK inhibition without compromising its anti-cancer activity. Our Approach includes in vitro analysis of 2 separate neuronal cell lines, behavioral analysis using sensory testing for CIPN, testing of cognitive impairment, and novel MouseWalker for gait changes in female mice using the two mouse cancer models. The proposed studies will demonstrate the role of the p38MAPK and JNK in cisplatin induced CRCI/CIPN, and translational potential for novel strategies to treat CRCI and CIPN. Due to health disparities, women suffer more disproportionately from cancer and pain-related treatment than men. Therefore, testing our hypothesis in female mice is expected to significantly advance the understanding and treatment of cisplatin-induced neurotoxic side effects and improve the quality of life for women with cancer. Nevertheless, we expect that these findings may also apply to cisplatin- induced neurotoxicity in males and to other cancers than ovarian and breast cancers.
化疗相关的认知障碍(CRCI、化学行为)、化疗所致的周围神经病变 (CIPN)和步态变化是铂类药物(如顺铂)治疗癌症的衰弱副作用, 紫杉烷和长春花碱。顺铂被广泛用作治疗卵巢恶性肿瘤的化疗药物。 超过70%的女性报告在治疗期间或完成治疗后经历了CRCI、CIPN和/或跌倒,损害 他们的生活质量。这些神经毒性损伤也会影响顺铂的治疗,影响 疾病的发展。目前,还没有FDA批准的临床干预措施来治疗CRCI和 CIPN。从机制上讲,顺铂诱导的神经元毒性源于核和线粒体DNA损伤, 和氧化应激,诱导丝裂原活化蛋白激酶(MAPK)p38MAPK的激活 和c-jun氨基末端激酶(JNK),导致神经元凋亡。我们的初步数据显示,在体外 小分子抑制剂对p38MAPK的药理抑制作用和SP600125对p38MAPK和SP600125的抑制作用 JNK,防止顺铂引起的树突棘分支和密度的减少。根据这些数据,我们 假设抑制p38MAPK/JNK通路将阻止顺铂诱导的神经元 细胞凋亡和损伤,导致认知障碍、步态改变和神经病变的减轻 与CRCI和CIPN相关的疼痛。在这个项目中,我们建议确定:(1)顺铂诱导的p38 利用体外药理学,MAPK/JNK信号通路在结构和功能神经元损伤中的基础 抑制和siRNA沉默;(2)奈法帕莫特和SP600125预防顺铂所致的神经病变和步态 C57BL/6小鼠ID8同基因上皮性卵巢癌和转基因乳腺癌的变化 (3)p38MAPK/JNK抑制顺铂的神经毒性作用 而不影响其抗癌活性。我们的方法包括两个独立的神经细胞的体外分析。 LINES,使用CIPN感觉测试的行为分析,认知障碍测试,以及新颖 MouseWalker使用两种小鼠癌症模型研究雌性小鼠步态变化。拟议的研究将 证明p38MAPK和JNK在顺铂诱导的CRCI/CIPN中的作用,以及 治疗CRCI和CIPN的新策略。由于健康差距,女性更不成比例地患有 癌症和疼痛相关的治疗要比男性多。因此,在雌性小鼠身上测试我们的假设有望 显著提高对顺铂所致神经毒性副作用的认识和治疗水平 癌症女性的生活质量。然而,我们预计这些发现也可能适用于顺铂- 对男性以及对卵巢癌和乳腺癌以外的其他癌症的神经毒性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniela Annenelie Bota其他文献

Daniela Annenelie Bota的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniela Annenelie Bota', 18)}}的其他基金

Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system
靶向 p38/JNK MAPK 改善顺铂引起的神经系统不良后遗症
  • 批准号:
    10437925
  • 财政年份:
    2021
  • 资助金额:
    $ 61.31万
  • 项目类别:
Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system
靶向 p38/JNK MAPK 改善顺铂引起的神经系统不良后遗症
  • 批准号:
    10285939
  • 财政年份:
    2021
  • 资助金额:
    $ 61.31万
  • 项目类别:
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma
靶向线粒体 Lon 蛋白酶作为胶质母细胞瘤的新疗法
  • 批准号:
    10832278
  • 财政年份:
    2020
  • 资助金额:
    $ 61.31万
  • 项目类别:
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma
靶向线粒体 Lon 蛋白酶作为胶质母细胞瘤的新疗法
  • 批准号:
    10407014
  • 财政年份:
    2020
  • 资助金额:
    $ 61.31万
  • 项目类别:
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma
靶向线粒体 Lon 蛋白酶作为胶质母细胞瘤的新疗法
  • 批准号:
    10633279
  • 财政年份:
    2020
  • 资助金额:
    $ 61.31万
  • 项目类别:
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma
靶向线粒体 Lon 蛋白酶作为胶质母细胞瘤的新疗法
  • 批准号:
    10406778
  • 财政年份:
    2020
  • 资助金额:
    $ 61.31万
  • 项目类别:
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma
靶向线粒体 Lon 蛋白酶作为胶质母细胞瘤的新疗法
  • 批准号:
    10054091
  • 财政年份:
    2020
  • 资助金额:
    $ 61.31万
  • 项目类别:
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma
靶向线粒体 Lon 蛋白酶作为胶质母细胞瘤的新疗法
  • 批准号:
    10228075
  • 财政年份:
    2020
  • 资助金额:
    $ 61.31万
  • 项目类别:
Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma
靶向线粒体 Lon 蛋白酶作为胶质母细胞瘤的新疗法
  • 批准号:
    10449732
  • 财政年份:
    2020
  • 资助金额:
    $ 61.31万
  • 项目类别:
Mechanisms of Chemotherapy Induced Cognitive Defects
化疗引起认知缺陷的机制
  • 批准号:
    8636500
  • 财政年份:
    2011
  • 资助金额:
    $ 61.31万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.31万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 61.31万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 61.31万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.31万
  • 项目类别:
    Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 61.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.31万
  • 项目类别:
    Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 61.31万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 61.31万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 61.31万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 61.31万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了